Myelodysplastic Syndrome
Myelodysplastic Syndrome
Advertisement
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Read More
Ariel JonesMyelodysplastic Syndrome | October 12, 2021
Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for ...
Ariel JonesMyelodysplastic Syndrome | October 7, 2021
For post-transplant disease control in patients with myelodysplastic syndromes (MDS), donor lymphocyte infusion (DLI) has ...
Ariel JonesMyelodysplastic Syndrome | September 13, 2021
Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine ...
Ariel JonesMyelodysplastic Syndrome | August 31, 2021
Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival ...
Ariel JonesMyelodysplastic Syndrome | August 11, 2021
In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity ...
Keightley AmenMyelodysplastic Syndrome | June 23, 2021
Treatment with enasidenib, a small molecule inhibitor of mutant IDH2, showed promising clinical activity in patients with ...
Kerri FitzgeraldMyelodysplastic Syndrome | February 1, 2021
A study published in Hematology, Transfusion & Cell Therapy found that FLT3, NPM1, IDH1, and IDH2 gene mutations may ...
Kerri FitzgeraldMyelodysplastic Syndrome | January 18, 2021
A study published in Cancer Causes & Control observed that smoking, history of autoimmune disease, and benzene exposure ...
Kerri FitzgeraldMyelodysplastic Syndrome | January 18, 2021
The use of poly (ADP-ribose) polymerase (PARP) inhibitors increased the risk of developing myelodysplastic syndromes (MDS) ...
Advertisement
Advertisement
Advertisement